Brightgene Bio-medical Technology Co Ltd
688166
Company Profile
Business description
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
Contact
Xinghu Street, Industrial Park
Building C25-C28, Bio-Nano Park, No. 218
Suzhou215123
CHNT: +86 51262620988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,151
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.10 | 46.00 | 0.51% |
| CAC 40 | 7,870.34 | 65.37 | 0.84% |
| DAX 40 | 24,377.50 | 191.91 | 0.79% |
| Dow JONES (US) | 44,911.26 | 11.01 | -0.02% |
| FTSE 100 | 9,177.24 | 12.01 | 0.13% |
| HKSE | 25,519.32 | 94.35 | -0.37% |
| NASDAQ | 21,710.67 | 2.47 | -0.01% |
| Nikkei 225 | 42,866.38 | 217.12 | 0.51% |
| NZX 50 Index | 12,843.50 | 9.42 | 0.07% |
| S&P 500 | 6,468.54 | 1.96 | 0.03% |
| S&P/ASX 200 | 8,873.80 | 46.70 | 0.53% |
| SSE Composite Index | 3,666.44 | 17.02 | -0.46% |